John Hussman's SRPT Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 147,000 shares of Sarepta Therapeutics, Inc. (SRPT) worth $2.64 M, representing 0.61% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 6 quarters.
Based on 13F filings, John Hussman has maintained this position in SRPT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 147,000 shares. Largest reduction occurred in Q1 2026, reducing 63,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +147,000 | New Buy | 147,000 | $17.97 |
| Q1 2026 | -63,000 | Sold Out | 0 | $0.00 |
| Q4 2025 | -21,000 | Reduce 25.00% | 63,000 | $21.52 |
| Q3 2025 | +21,000 | Add 33.33% | 84,000 | $19.27 |
| Q2 2025 | +52,500 | Add 500.00% | 63,000 | $17.10 |
| Q1 2025 | +10,500 | New Buy | 10,500 | $63.82 |
John Hussman's Sarepta Therapeutics Investment FAQs
John Hussman first purchased Sarepta Therapeutics, Inc. (SRPT) in Q1 2025, acquiring 10,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Sarepta Therapeutics, Inc. (SRPT) for 6 quarters since Q1 2025.
John Hussman's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q2 2026, adding 147,000 shares worth $2.64 M.
According to the latest 13F filing for Q2 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 147,000 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $2.64 M.
As of the Q2 2026 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.61% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 147,000 shares, as reported at the end of Q2 2026.